PRT2527
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 274 patients (estimated)
- Sponsors
- Prelude Therapeutics
- Collaborators
- BeiGene
- Tags
- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1989
- NCT Identifier
- NCT05665530
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.